You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Condition:   Epidermolysis Bullosa
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017
Body: Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: GVHD Prophylaxis;   Drug: Gemtuzumab Ozogamicin;   Drug: Anti-Thymocyte Globulin;   Drug: Isotretinoin
Sponsor:   Columbia University
Active, not recruiting - verified July 2017
Body: Condition:   Severe Thalassemia
Intervention:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Sponsors:   Washington University School of Medicine;   New England Research Institutes;   Pediatric Blood and Marrow Transplant Consortium
Unknown status
Body: Conditions:   Leukemia;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   MDS;   Multiple Myeloma
Interventions:   Drug: EPOCH-F/R;   Drug: FLAG;   Drug: Transplant Preparative Regimen (Flu/Cy/Mes);   Drug: GVHD Prophylaxis (tacrolimus and sirolimus);   Procedure: Double Cord Blood Transplantation
Sponsor:   National Cancer Institute (NCI)
Terminated - verified May 20, 2013
Body: Condition:   Congenital Pediatric Disorders
Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified September 2017
Body: Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG);   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections;   Drug: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI);   Drug: Fludarabine, Busulfan, and ATG
Sponsor:   University of Chicago
Active, not recruiting - verified July 2017
Body: Conditions:   MDS;   Immunodeficiency;   GATA2
Interventions:   Drug: Cyclophosphamide (CTX, Cytoxan);   Drug: Fludarabine(Fludara,Berlex Laboratories);   Procedure: Total Body Irradiation (TBI);   Procedure: Allogeneic HSC;   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting
Body: Condition:   Non-Malignant
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2017
Body: Conditions:   Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myeloid, Acute;   Burkitt Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
Interventions:   Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation;   Biological: GVHD prophylaxis
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
Completed
Body: Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Duke University
Completed
Body: Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Immunodeficiencies;   Anemia
Interventions:   Drug: TBI, Thiotepa, Cyclophosphamide, ATG;   Drug: Busulfan, Melphalan, Rabbit ATG;   Drug: Busulfan, Fludarabine, Alemtuzumab;   Drug: Busulfan, Fludarabine, Rabbit ATG;   Drug: Fludarabine, Cyclophosphamide, ATG;   Drug: Busulfan, Cyclosphosphamide, Rabbit ATG,
Sponsor:   Columbia University
Terminated
Body: Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   RAEB-2;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified June 2017
Body: Condition:   Severe Osteopetrosis
Interventions:   Procedure: umbilical cord blood transplantation;   Drug: Campath-1H;   Radiation: Total Lymphoid Irradiation;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Procedure: marrow graft transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Unknown status
Body: Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia;   Hodgkins Lymphoma
Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified September 2017
Body: Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Suspended

Pages